BioPharmSignal logoBioPharmSignal

Biotech News

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PolyPid (PYPD)PolyPidEarnings

FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Commercialization Partnership with Azurity Pharmaceuticals; $30 Million in Upfront and Near-Term Milestones Achieved

Related news

PYPDPolyPid2026-05-13 11:30 EST

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PYPDPolyPid2026-02-11 12:30 EST

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

View all latest news

PolyPid

Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. This approach is intended to improve local exposure while limiting systemic treatment burden. PLEX Technology The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control...

Recent company news

PYPDPolyPid2026-08-12 11:30 EST

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PYPDPolyPid2026-07-30 12:00 EST

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

PYPDPolyPid2026-07-29 12:30 EST

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PYPDPolyPid2026-07-21 11:30 EST

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PYPDPolyPid2026-06-01 12:30 EST

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

Stock data

Close
4.77 USD
Market cap
93.38M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States